Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
Bellicum Pharmaceuticals, Inc. (BLCM)
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.bellicum.com/investor-overview
Company Research
Source: GlobeNewswire
SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced additional follow-up results from a subset of children with high-risk/relapsed acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The data showed durable anti-leukemic effects in patients treated with rivo-celTM (rivogenlecleucel, formerly BPX-501) following aßT-cell and B-cell depleted allogeneic hematopoietic stem cell transplantation (HSCT). The data were reviewed in an oral presentation today at the 60th Annual Meeting of the American Society of Hematology (ASH 2018) by Principal Investigator Franco Locatelli, M.D., Ph.D., Director of the Department of Hematology and Oncology and Cell/Gene Therapy at Ospedale Pediatrico Bambino Gesù in Rome, Italy. “Cancer recurrence is one of the primary factors affecting the success rate of allogeneic HS
Show less
Read more
Impact Snapshot
Event Time:
BLCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCM alerts
High impacting Bellicum Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BLCM
News
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
BLCM
Sec Filings
- 3/1/24 - Form 15-12G
- 2/27/24 - Form EFFECT
- 2/27/24 - Form EFFECT
- BLCM's page on the SEC website